Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28889016 | 0.91 | MAPT (0.42) | MAPTALDH1A1LMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL8404115 | 0.86 | FAAH (0.39) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL452864 | 0.85 | ALDH1A1 (0.39) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL912548 | 0.85 | MAPT (0.38) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL230068 | 0.84 | ALDH1A1 (0.50) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL334795 | 0.83 | MAPT (0.44) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL28170409 | 0.82 | FAAH (0.54) | ALDH1A1MEN1KMT2ATDP1LMNA | |
| Ammonia Solution, Strong SCHEMBL27830684 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL26658212 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL28054134 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605622-A | Aliphatic polyester with malonic acid structure and preparation method and application thereof | 苏州瀚海新材料有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-107512900-A | A kind of light heat insulating material and preparation method thereof | 浙江中泰绝热材料有限公司 | 2017-12-26 | — | — | CN | claimed |
| CN-104513327-B | Olefin polymerization catalyst composition and applications thereof | 中国石油化工股份有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-105315390-A | Catalyst composition for olefin polymerization and application thereof | BEIJING COMBINE TECH CO LTD | 2016-02-10 | — | — | CN | claimed |
| CN-104513330-A | Catalyst system used in olefin polymerization and application thereof | CHINA PETROLEUM & CHEMICAL | 2015-04-15 | — | — | CN | claimed |
| CN-104513327-A | Olefin polymerization catalyst composition and applications thereof | CHINA PETROLEUM & CHEMICAL | 2015-04-15 | — | — | CN | claimed |
| CN-104513332-A | Catalyst system used in olefin polymerization and application thereof | CHINA PETROLEUM & CHEMICAL | 2015-04-15 | — | — | CN | claimed |
| CN-104194978-A | Enteroscope detergent | LIU XINXIA | 2014-12-10 | — | — | CN | claimed |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-114605622-A | Aliphatic polyester with malonic acid structure and preparation method and application thereof | 苏州瀚海新材料有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | CAYMAN CHEMICAL COMPANY, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2014015247-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014015246-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| CN-103483169-A | Bicyclic gamma-amino acid derivative | DAIICHI SANKYO CO LTD | 2014-01-01 | — | — | CN | disclosed |
| CN-1946293-A | Pyrazolopyrimidines for controlling undesired microorganisms | BAYER CROPSCIENCE AG (DE) | 2007-04-11 | — | — | CN | disclosed |
| CN-1121906-C | Long-lived homogenous oxidation catalyst | UNIV CARNEGIE MELLON (US) | 2003-09-24 | — | — | CN | disclosed |
| CN-1230903-A | Long-lived homogenous oxidation catalyst | UNIV CARNEGIE MELLON (US) | 1999-10-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | MAPT 3228/4885ALDH1A1 654/4885MEN1 3177/4885 |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | MAPT 3228/4885ALDH1A1 654/4885MEN1 3177/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | MAPT 3228/4885ALDH1A1 654/4885MEN1 3177/4885 |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | PTGER4, PTGER1, PTGIR | MAPT 2798/4885ALDH1A1 710/4885MEN1 1206/4885 |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | MAPT 2798/4885ALDH1A1 710/4885MEN1 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.